Source - RNS
RNS Number : 3789J
Dechra Pharmaceuticals PLC
09 September 2016


Friday, 9 September 2016


Dechra® Pharmaceuticals PLC

(Dechra, Company or the Group)


Product approval


Dechra receive FDA approval for first US generic entrant antibiotic



Dechra is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) for a generic antibiotic.


The product is expected to be a first generic market entrant in a substantial antibiotic market; it is the first registration Dechra has achieved through Putney's development pipeline since it acquired the US-based business and clearly demonstrates the capabilities of our specialist pharma team, a key resource to the Group.


Commenting on the approval Dechra's Chief Executive Officer, Ian Page said:


"We are delighted to receive this approval which provides excellent growth opportunity for our US team and underpins our confidence in the strength of the recently acquired Putney business whilst further enhancing Dechra's position in the US market."



Enquiries to:

Dechra Pharmaceuticals PLC

Ian Page, Chief Executive Officer

Office:  +44 (0) 1606 814 730

e-mail: [email protected]

TooleyStreet Communications Ltd

Fiona Tooley, Director

Mobile: +44 (0) 7785 703 523

e-mail: [email protected]



About Dechra

Stock Code: Full Listing (Pharmaceuticals): DPH


Dechra is an international specialist veterinary pharmaceuticals and related products business.  Its expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide.  Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. 


The Group's Preliminary results for the year ended 30 June 2016 were released on 5 September 2016. For more information, please visit:



Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC. 




Market Abuse Regulation (MAR)

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.


This information is provided by RNS
The company news service from the London Stock Exchange